These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 38078745)

  • 1. Microbiota-mediated effects of Parkinson's disease medications on Parkinsonian non-motor symptoms in male transgenic mice.
    Radisavljevic N; Metcalfe-Roach A; Cirstea M; Tabusi MM; Bozorgmehr T; Bar-Yoseph H; Finlay BB
    mSphere; 2024 Jan; 9(1):e0037923. PubMed ID: 38078745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Gut Microbiota Alterations on Motor, Gastrointestinal, and Behavioral Phenotype in a Mouse Model of Parkinson's Disease.
    Radisavljevic N; Cirstea M; Bauer K; Lo C; Metcalfe-Roach A; Bozorgmehr T; Bar-Yoseph H; Brett Finlay B
    J Parkinsons Dis; 2022; 12(5):1479-1495. PubMed ID: 35599496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's Disease Medication Alters Small Intestinal Motility and Microbiota Composition in Healthy Rats.
    van Kessel SP; Bullock A; van Dijk G; El Aidy S
    mSystems; 2022 Feb; 7(1):e0119121. PubMed ID: 35076270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease.
    Koutzoumis DN; Vergara M; Pino J; Buddendorff J; Khoshbouei H; Mandel RJ; Torres GE
    Exp Neurol; 2020 Mar; 325():113159. PubMed ID: 31843492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curcumin-driven reprogramming of the gut microbiota and metabolome ameliorates motor deficits and neuroinflammation in a mouse model of Parkinson's disease.
    Cui C; Han Y; Li H; Yu H; Zhang B; Li G
    Front Cell Infect Microbiol; 2022; 12():887407. PubMed ID: 36034698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome.
    Hill-Burns EM; Debelius JW; Morton JT; Wissemann WT; Lewis MR; Wallen ZD; Peddada SD; Factor SA; Molho E; Zabetian CP; Knight R; Payami H
    Mov Disord; 2017 May; 32(5):739-749. PubMed ID: 28195358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis.
    Zhao Z; Ning J; Bao XQ; Shang M; Ma J; Li G; Zhang D
    Microbiome; 2021 Nov; 9(1):226. PubMed ID: 34784980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between gut microbiota characteristics and non-motor symptoms following pharmacological and surgical treatments in Parkinson's disease patients.
    Gorecka-Mazur A; Krygowska-Wajs A; Furgala A; Li J; Misselwitz B; Pietraszko W; Kwinta B; Yilmaz B
    Neurogastroenterol Motil; 2024 Aug; 36(8):e14846. PubMed ID: 38873926
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Chu C; Yu L; Li Y; Guo H; Zhai Q; Chen W; Tian F
    Nutrients; 2023 Apr; 15(7):. PubMed ID: 37049578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Dysbiosis and Dampened Gut Microbe Oscillation Precede Motor Dysfunction and Neuropathology in Animal Models of Parkinson's Disease.
    Liang F; Chen CY; Li YP; Ke YC; Ho EP; Jeng CF; Lin CH; Chen SK
    J Parkinsons Dis; 2022; 12(8):2423-2440. PubMed ID: 36155528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of fecal microbiota transplantation in Parkinson's disease patients with constipation.
    Kuai XY; Yao XH; Xu LJ; Zhou YQ; Zhang LP; Liu Y; Pei SF; Zhou CL
    Microb Cell Fact; 2021 May; 20(1):98. PubMed ID: 33985520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications.
    Menozzi E; Schapira AHV
    CNS Drugs; 2024 May; 38(5):315-331. PubMed ID: 38570412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pitx3-deficient developmental mouse model for fine motor, olfactory, and gastrointestinal symptoms of Parkinson's disease.
    Song B; Feldmann JW; Cao S; Feitosa M; Kong Y; Kim W; Schweitzer A; Leblanc P; Schweitzer JS; Kim KS
    Neurobiol Dis; 2022 Aug; 170():105777. PubMed ID: 35636646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson's disease.
    Hou YF; Shan C; Zhuang SY; Zhuang QQ; Ghosh A; Zhu KC; Kong XK; Wang SM; Gong YL; Yang YY; Tao B; Sun LH; Zhao HY; Guo XZ; Wang WQ; Ning G; Gu YY; Li ST; Liu JM
    Microbiome; 2021 Jan; 9(1):34. PubMed ID: 33517890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated multi-omics profiling highlights the benefits of resveratrol hydroxypropyl-β-cyclodextrin inclusion complex for A53T transgenic mice through the microbiota-gut-brain axis.
    Sun X; Feng S; Qin B; Ye J; Xie L; Gui J; Sang M
    Food Funct; 2024 Feb; 15(3):1489-1512. PubMed ID: 38227477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson's disease.
    Ghaisas S; Langley MR; Palanisamy BN; Dutta S; Narayanaswamy K; Plummer PJ; Sarkar S; Ay M; Jin H; Anantharam V; Kanthasamy A; Kanthasamy AG
    Neurotoxicology; 2019 Dec; 75():186-199. PubMed ID: 31505196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT4 Receptor is Protective for MPTP-induced Parkinson's Disease Mice Via Altering Gastrointestinal Motility or Gut Microbiota.
    Cui C; Shi Y; Hong H; Zhou Y; Qiao C; Zhao L; Jia X; Zhao W; Shen Y
    J Neuroimmune Pharmacol; 2023 Dec; 18(4):610-627. PubMed ID: 37782386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Trehalose Intake Modulates the Microbiota-Gut-Brain Axis and Is Neuroprotective in a Synucleinopathy Mouse Model.
    Pradeloux S; Coulombe K; Ouamba AJK; Isenbrandt A; Calon F; Roy D; Soulet D
    Nutrients; 2024 Sep; 16(19):. PubMed ID: 39408276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-Cell-Driven Inflammation as a Mediator of the Gut-Brain Axis Involved in Parkinson's Disease.
    Campos-Acuña J; Elgueta D; Pacheco R
    Front Immunol; 2019; 10():239. PubMed ID: 30828335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. More than constipation - bowel symptoms in Parkinson's disease and their connection to gut microbiota.
    Mertsalmi TH; Aho VTE; Pereira PAB; Paulin L; Pekkonen E; Auvinen P; Scheperjans F
    Eur J Neurol; 2017 Nov; 24(11):1375-1383. PubMed ID: 28891262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.